Camp4 Therapeutics Corp (CAMP) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-03

Key Insights

Michael F. MacLean, a director of Camp4 Therapeutics Corp, has acquired 56,000 stock options with an exercise price of $4.46 and a 10-year expiration date.
The stock options vest in equal monthly installments over a period of three years, indicating a long-term commitment to the company.
Insider ownership and alignment with shareholders is a positive sign for the company's future prospects.

Want the newest filings?

This analysis covers the filing from 2026-04-03. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-03

Josh Mandel-Brehm, the CEO and Director of Camp4 Therapeutics Corp, has been granted a stock option to acquire 580,000 shares of the company's common stock, vesting over a 4-year period.
The exercise price of the stock option is $4.46 per share, which may suggest the company's stock price is currently trading at that level or above.
The timely filing of this Form 4 indicates the company's commitment to transparency and compliance with regulatory reporting requirements.

Filed: 2026-04-03

Kelly Gold, the Chief Financial Officer of Camp4 Therapeutics Corp, acquired 215,000 stock options on April 1, 2026 with an exercise price of $4.46 and a 10-year expiration date.
The stock option grant vests in equal monthly installments over a period of four years, indicating a long-term commitment from the CFO to the company.
Insider buying of this magnitude, representing a sizable portion of the CFO's compensation, suggests the executive team's confidence in the company's future prospects.

Filed: 2026-04-03

Yuri Maricich, the Chief Medical Officer of Camp4 Therapeutics Corp (CAMP), has acquired 215,000 stock options with an exercise price of $4.46 on April 1, 2026, indicating the company's confidence in its future growth and management's alignment with shareholder interests.
The options vest over a four-year period, suggesting a long-term commitment from the executive and the company's focus on building sustainable value.
Insider buying is generally seen as a positive signal, as executives are typically well-informed about the company's prospects and willing to invest in its future.

Filed: 2026-04-03

Daniel Tardiff, the Chief Scientific Officer, acquired 170,000 stock options with an exercise price of $4.46 and a 10-year expiration date. This suggests he is confident in the company's long-term prospects.
The options vest over 4 years, aligning Tardiff's interests with shareholders and incentivizing him to drive the company's scientific and operational success.
Insider buying is a positive signal, as it indicates Tardiff's belief in the company's future growth potential and willingness to invest his own capital.

Other reports for Camp4 Therapeutics Corp

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.